Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists probe body's own fat-making signals for obesity clues

NCT ID NCT07567287

Knowledge-focused Sponsor: Centre Hospitalier Universitaire Dijon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 11, 2026 · Updated 1 time

Summary

This study looks at how certain natural chemicals (endocannabinoids) influence the development of fat cells from stem cells found in belly fat. Researchers will take small fat samples from 30 people undergoing abdominal surgery, including healthy controls, people with obesity, and those with both obesity and type 2 diabetes. The goal is to understand these processes better, which could lead to new treatments for obesity and diabetes in the future.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2026

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Control group : * Men or postmenopausal women aged 18 to 80 * Individuals who have provided their free and informed written consent * Individuals scheduled to undergo abdominal surgery * Non-diabetic obese individuals : * Men or postmenopausal women aged 18 to 80 * BMI \> 30 - Individuals who have provided written, free, and informed consent * Scheduled to undergo abdominal surgery * Obese individuals with diabetes : * Men or postmenopausal women aged 18 to 80 with type 2 diabetes not treated with insulin or a GLP-1 agonist * BMI \> 30 * Individuals who have provided written, free, and informed consent and are scheduled to undergo abdominal surgery Exclusion Criteria : * Control group : * Individuals not enrolled in or eligible for a social security program * Individuals subject to legal guardianship (curatorship, guardianship) * Individuals subject to judicial protective measures * Pregnant women, women in labor, or breastfeeding women * Adults who are legally incapacitated or unable to give consent * Minors * BMI \> 30 * Diabetes * Chronic inflammatory disease * Cancer undergoing chemotherapy or having undergone chemotherapy within the past year * Gastrointestinal cancer with recent weight loss and/or malnutrition * Known metastatic cancers * Cancers undergoing long-term hormonal therapy * Any positive result for screening for human immunodeficiency virus (HIV) infection, hepatitis B surface antigen testing, or testing for antibodies against the hepatitis C virus (HCV) with a positive HCV RNA test. * Non-diabetic obese individuals : * Individuals not enrolled in or eligible for a social security program * Individuals subject to legal guardianship (curatorship, guardianship) * Individuals subject to judicial protective measures * Pregnant women, women in labor, or breastfeeding women * Adults who are legally incapacitated or unable to give consent * Minors * Diabetes * Chronic inflammatory disease * Cancer undergoing chemotherapy or having undergone chemotherapy within the past year * Gastrointestinal cancer with recent weight loss and/or malnutrition * Known metastatic cancers * Cancers undergoing long-term hormonal therapy, * Any positive result for screening for human immunodeficiency virus (HIV) infection, hepatitis B surface antigen, or antibodies to hepatitis C virus (HCV) with a positive HCV RNA test. * Obese individuals with diabetes * Individuals not enrolled in or not eligible for a social security program * Individuals subject to legal guardianship (curatorship, guardianship) * Individuals subject to judicial protective measures * Pregnant women, women in labor, or breastfeeding women * Adults who are legally incapacitated or unable to give consent * Minors * Diabetes * Chronic inflammatory disease * Cancer undergoing chemotherapy or having undergone chemotherapy within the past year * Gastrointestinal cancer with recent weight loss and/or malnutrition * Known metastatic cancers * Cancers undergoing long-term hormonal therapy, * Any positive result for screening for human immunodeficiency virus (HIV) infection, hepatitis B surface antigen, or antibodies against hepatitis C virus (HCV) with a positive HCV RNA test.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Differenciation of stromal-vascular fraction cells are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

obesity disorder type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Differenciation of stromal-vascular fraction cells

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Chu Dijon Bourgogne

    RECRUITING

    Dijon, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.